Navigation Links
Elusys Releases New Data On Anthrax Anti-Toxin Administered Via Intramuscular Injection From Three Recent Animal Studies
Date:7/31/2013

challenge with B. anthracis. All control animals developed bacteremia by 56 hours after challenge while 86% (36/42) of animals dosed with ETI-204 never developed detectable levels of bacteremia.

"These data demonstrate the considerable activity obtained with intramuscular (IM) administration of the anti-toxin when given either before or after challenge in animal models of inhalational anthrax. We are extremely pleased that a single dose of ETI-204 demonstrated protection against inhalational anthrax infection," said Leslie Casey, PhD, Vice President, Research. "We look forward, in the very near term, to initiating a clinical study in healthy subjects to assess the pharmacokinetics and tolerability of IM administration in humans."

Anthrax is a life-threatening infectious disease caused by the bacterium Bacillus anthracis and remains one of the nation's top biowarfare threats. Much of the morbidity and mortality of anthrax can be attributed to anthrax toxins. Inhaled anthrax is often fatal, despite treatment with antibiotics. In the 2001 anthrax letter attacks, inhalational anthrax had a fatality rate of approximately 50% in humans infected, even when victims were given antibiotics and supportive hospital care.

ETI-204 is the only anthrax anti-toxin in advanced stages of development that is formulated as a solution and is being investigated for both IV and IM administration. A product that can be given IM as well as IV is highly desirable because it could provide the capability to more rapidly administer product to people outside of a hospital setting or where IV administration is not feasible.

About ETI-204
ETI-204 is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins by binding to Protective Antigen. It is an investigational agent being deve
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Elusys Awarded Additional $50.2 Million Under An Exisiting U.S. Government Contract To Support Final Stages Of Development Of ETI-204, For Treatment Of Inhalational Anthrax
2. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
3. HCCS Releases ICD-10 Countdown Clock With Integrated CMS Twitter Tweets
4. eCareSoft Releases eCS Cirrus™
5. AtheroNova Releases 2011 Financial Results
6. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
7. ILVO-T&V Belgium Releases Validation Report of the Charm Sciences Beta-lactam and Tetracycline 2-minute Test for Raw Commingled Milk
8. ISPE Releases New Guidance for Designing and Constructing Packaging, Labeling and Warehousing Facilities
9. Happtique Releases Draft App Certification Program Standards For Public Comment
10. ClearCanvas Releases New Workstation Products Designed to Assist With Image Sharing
11. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open Solution QuantAnalytics(TM) ... management and clinical markets. The software increases the speed ... users to highlight and review results that are of ... to filter results by group or based on a ... need to sift through analytes of no interest. In ...
(Date:10/22/2014)... 22, 2014 Physicians Choice Laboratory ... pharmacogenetics menu, which enables healthcare providers to individualize ... PCLS’s evidence-based results, healthcare providers are better able ... therapy, while minimizing risks for adverse drug reactions ... to the FDA [1] more than 2.2 million ...
(Date:10/22/2014)... Research and Markets  has announced the addition of ... Geography - Global Analysis and Forecast (2014 - 2020)" ... electronics, also called as polymer electronics or plastic electronics, ... small conductive molecules and electrically conductive polymers. It is ... carbon based, made using synthetic strategies developed in the ...
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... SOUTH SAN FRANCISCO, Calif., May 15 Poniard Pharmaceuticals, ... focused on oncology, today announced that it has filed ... Securities and Exchange Commission (SEC) that, when declared effective ... time to offer and sell up to $60 million ...
... JOLLA, Calif., May 15 Fate Therapeutics, ... exclusive intellectual property rights jointly owned by Children,s Hospital ... covers compositions and methods for supporting hematopoietic stem cells. ... director of the Stem Cell Program at Children,s Hospital ...
... Shandong, China, May 15 /PRNewswire-Asia-FirstCall/ -- China,Biologic Products, ... the,Company,), one of the leading plasma-based pharmaceutical companies ... that the Company,s,management will present at the upcoming ... New York, NY on May 18, 2009 and ...
Cached Biology Technology:Poniard Pharmaceuticals Files Shelf Registration 2Poniard Pharmaceuticals Files Shelf Registration 3Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 2Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 3China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 2China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 3China Biologic Products to Present at CCG IR's China Rising Conference and Oppenheimer's China Dragon Call Conference in New York 4
(Date:10/17/2014)... critical and pertinent for practicing physicians and clinicians given ... The Journal, Disaster Medicine and Public Health Preparedness ... Public Health, to surround the public, medical professionals and ... , On October 17, the journal published ... was prepared by Dr. Eric Toner, internist and emergency ...
(Date:10/17/2014)... from the University of Copenhagen have shown for the ... lungs of Cystic fibrosis patients, giving them the opportunity ... in chronic infections. , The study also discovered the ... (CF) patients was halted or slowed down by the ... all the oxygen and helped "suffocate" the bacteria, forcing ...
(Date:10/16/2014)... the human body. Battles are won, lost or ... this stalemate—known as tumor dormancy—can last up to ... that is poorly understood. , A new ... Torquato, a Professor of Chemistry at Princeton University, ... and the switch to a malignant state. Published ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Modeling tumor dormancy 2
... cardiovascular disorders and old age have one thing in ... scientists have observed oxidative changes in important biomolecules. These ... free radicals that are formed as a by-product of ... acids. Today, reactive oxygen molecules are no longer ...
... CAMBRIDGE, Mass.--As Charles Darwin showed nearly 150 years ago, bird ... team of MIT mathematicians and engineers has now explained exactly ... gravity and transport food into their mouths. The phalarope, ... interactions between its beak and water droplets to propel bits ...
... Contrary to long-held assumptions, high-salt diets may ... investigators from the Albert Einstein College of Medicine ... examining dietary intake among a nationally representative sample ... actually observed a significantly increased risk of death ...
Cached Biology News:Biosensor for measuring stress in cells 2MIT solves gravity-defying bird beak mystery 2MIT solves gravity-defying bird beak mystery 3New study casts further doubt on risk of death from higher salt intake 2
DTT, 25g...
... Agarose overlays are commonly used ... commercial "DNA grade" agaroses either ... to insect cells or lack ... obtain good overlays. Novagen's BacPlaque ...
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
...
Biology Products: